| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the Department of Neurology,*
Nagoya University
School of Medicine, Nagoya, Japan; Laboratory of Electron
Microscopy,
Aichi Medical University, Aichi,
Japan; Department of Neurology,
University of
Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and
Department of Internal Medicine§
and
Institute for Medical Science of Aging,¶
Aichi
Medical University, Aichi, Japan
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Other disorders caused by CAG repeat expansion include Huntington's disease (HD),9 dentatorubral-pallidoluysian atrophy (DRPLA),10,11 Machado-Joseph disease (MJD),12 and spinocerebellar ataxia type 1 (SCA1),13 type 2 (SCA2)1416, type 6 (SCA6),17 and type 7 (SCA7).18 These disorders share several characteristics that are likely relevant to a common pathological mechanism leading to selective neuronal loss. The mechanism is thought to be a toxic gain of function of the mutant gene products19,20 involving cell-specific protein-protein or protein-nucleic acid interactions with the products of the mutant genes.21-26 Intranuclear inclusions of the mutant proteins have recently been documented in the neurons of HD,27,28 MJD,29,30 SCA1,26,31 DRPLA,3 and SBMA motor neurons,33 as well as in the transgenic models of HD34,35 and SCA1.26 In all of these disorders, the inclusions can be labeled with antibodies (Abs) to the disease protein product and to ubiquitin. The inclusions are so far detected in the neurons of the affected brain areas of each disease, and rarely in other brain regions,27-32 despite the ubiquitous expression of the disease gene product.36 Furthermore, in HD, there is a correlation between increasing CAG repeat length and increasing density of the inclusions.36 Thus, intranuclear inclusions of mutant protein mediated by polyglutamine-directed aggregation are thought to have a primary pathogenic role in neuronal loss for these CAG repeat diseases.26-35
In this study, we demonstrate that nuclear inclusions of mutant AR protein occur in selected nonneural tissues as well as neural tissues in SBMA.
| Materials and Methods |
|---|
|
|
|---|
Various portions of brain, spinal cord, peripheral nerve, muscle, and nonneural visceral organs were sampled from five autopsied patients with SBMA (three of whom were processed for frozen samples and all five fixed in formalin). These patients were 54 to 82 years of age at death, and each showed a typical clinical phenotype of SBMA, with dysphagia, bulbar and extremity muscle weakness, and atrophy with fasciculation. Gynecomastia and diabetes mellitus were present in four patients. Duration from onset to death was 9 to 23 years, and the causes of death were empyema, bronchiectasis, and gastric cancer. The CAG repeat lengths of the AR gene determined in blood samples were 40 to 52. Tissue samples for immunohistochemical analysis were obtained at autopsy, frozen in liquid nitrogen, and stored at -80°C or were fixed in 10% buffered formalin and processed for paraffin section. The pathological features of these cases were also typical for SBMA,2,3 with minimal variation in extent among the patients; the spinal, bulbar and pontine motor neurons were extensively depleted, with mild gliosis; sensory neurons were mildly affected, with occasional Nageotte's nodules; the posterior column of the spinal cord was depleted in a rostrally accentuated manner; the muscles were chronically denervated, and the sural nerve myelinated fibers were moderately depleted. Testicular atrophy and fatty liver changes were also present. Other portions of the central nervous system and visceral organs were normal except for pulmonary infection in all patients and gastric cancer in one patient.
Control tissue samples were obtained from four male autopsied patients ages 54 to 71 years, who died of nonneurological diseases. The AR CAG repeat lengths of the controls were 19 to 24.
All autopsies were performed within 6 hours postmortem.
Abs to AR Protein Used in This Study
Several polyclonal and monoclonal Abs that specifically recognize
the AR protein were used in this study (Figure 1)
: 2F12 (mouse
monoclonal Ab (immunoglobulin (Ig) G), NovoCastra, Newcastle, UK),
generated against a recombinant protein of 321 amino acids from the N
terminus of the human AR; PG-21 (rabbit polyclonal Ab (IgG), Affinity
BioReagents, Golden, CO) and AR(N-20)(rabbit polyclonal Ab
(IgG), Santa Cruz Biotechnology, Santa Cruz, CA), which recognize 21
and 20 amino acid residues of the N terminus of the AR, respectively;
AR52 (rabbit polyclonal Ab (IgG), kindly provided by Dr. E. Wilson,
University of North Carolina, Chapel Hill, NC), which recognizes the
DNA-binding domain of the AR; and 5F4 (mouse monoclonal Ab (IgM),
kindly provided by Dr. T Demura, Department of Urology, Hokkaido
University, Hokkaido, Japan) and AR(C-19) (rabbit polyclonal Ab
(IgG), Santa Cruz Biotechnology), which recognizes the C terminus of
the human AR. Characterization and binding specificities of all of
these Abs to human AR were previously described.33,37-39
Anti-ubiquitin Ab (rabbit polyclonal Ab (IgG), Dakopatts, Glostrup,
Denmark) was also used.
|
Cryostat sections of 8 µm were prepared from the frozen tissues of SBMA patients and controls, quickly dried, and lightly fixed with Zamboni fixative for 10 minutes. Then the tissue sections were washed, blocked with normal horse serum (1:20), and incubated with Abs against AR, ubiquitin, or affinity-purified mouse IgG1 at concentrations of 0.5 to 4 µg/ml. Endogenous peroxidase was blocked by preincubation of tissue sections with 0.3% H2O2 in methanol for 30 minutes. Endogenous biotin was also blocked by incubation with an avidin-biotin blocking kit (Vector Laboratories, Burlingame, CA). Immune complexes were visualized using the avidin-biotinylated horseradish peroxidase system (Elite Vector kit from Vector Laboratories) and 3,3'-diaminobenzidine (Dakopatts) substrate. Sections were counterstained with methyl green. For paraffin-embedded samples, the 4-µm tissue sections were deparaffinized in xylene, hydrated with alcohol, and then heated in a microwave oven for 5 minutes. The tissue sections were then processed in the same way as those for the frozen tissue sections. Immune complexes were visualized using the tyramide signal amplification system (New England Nuclear, Boston, MA) following the manufacturer's protocol.
For electron microscopic immunohistochemistry, buffered formalin-fixed, paraffin-embedded tissue sections were immunostained with Abs against AR and then incubated with horseradish peroxidase-labeled second Ab (Amersham, Poole, UK). The tissue sections were then visualized with 3,3'-diaminobenzidine (Dakopatts), fixed with 2% osmium tetroxide in 0.1 mol/L phosphate buffer, pH 7.4, and dehydrated in an alcohol gradient and embedded in epoxy resin, from which ultrathin sections were obtained and then observed under an electron microscope (Hitachi H-7000).
CAG Repeat Length Assessment for Normal and Mutant AR Genes
CAG repeat length of the AR gene was determined on the autopsied tissue samples using methods described previously.5,40
| Results |
|---|
|
|
|---|
|
|
|
|
|
The morphological appearance of the motor neurons and nonneural cells with nuclear inclusions was indistinguishable from those without inclusions.
Neural and nonneural tissues from four control cases were also examined in the same manner as that for SBMA cases, but the inclusions were not seen in the control individuals.
| Discussion |
|---|
|
|
|---|
The electron microscopic appearance of the AR-positive dense aggregates with similar granular size without limiting membrane was common to both neural and nonneural tissues. Furthermore, a characteristic selective staining pattern of the nuclear inclusions seen with only Abs recognizing N-terminal 20 and 21 amino acids of the AR protein was also common among the neural and nonneural tissues. These observations strongly suggest that same mechanism is involved in formation of AR-positive components in the nuclear inclusions in both the neural and nonneural tissues. The immunostaining pattern suggests that only a small portion of the N terminus of the AR protein is available as an epitope in the nuclear inclusions, and other portions of the AR may be masked within the inclusions of the mutant protein, or alternatively, the AR protein may be cleaved by proteolytic activity resulting in N-terminal fragments that participate in the aggregation, as was suggested in other polyglutamine diseases.26-36,41 In addition, these AR nuclear inclusions are ubiquitinated in the nonneural as well as neural tissues, indicating that the nuclear inclusion is a pathological structure of the mutant AR, even in the nonneural tissues, where the pathological involvement is not apparent. Our electron microscopic and light microscopic immunohistochemical data indicate that nuclear inclusions in both motor neurons and nonneural tissues are identical in morphological and immunochemical features. Furthermore, absence of filamentous structures in the nuclear inclusion of SBMA was different from observations in HD27 and MJD.30 This difference may suggest that the pathway of the nuclear aggregation is different among the different protein products or, alternatively, may represent variances in sample preparation.
In polyglutamine diseases that have been analyzed to date, the nuclear inclusions have been shown to occur selectively in neurons of the affected brain regions. The selective occurrence of nuclear inclusions in the affected cells of central nervous system in SBMA that we observed in this study agrees well with observations of HD, MJD, SCA1, and DRPLA,27-32 as well as our previous observations in SBMA.33 However, the appearance of similar nuclear inclusions in the nonneural tissues observed in this study is novel. It is an important question why the neurons are selectively affected despite the presence of nuclear inclusions in both the affected neurons and nonaffected nonneural tissues. The cells of the nonneural tissues are mitotic cells in contrast to motor neurons; the epidermal cells in the scrotal and dermal skin and epithelial cells in the kidney tubules are all capable of mitosis in adulthood, and are eventually replaced by newly generated cells. Hence, those cells with toxic effects associated with the nuclear inclusions may be replaced by turnover. It may also be that neurons are particularly susceptible to whatever deleterious effects the inclusions may have. As demonstrated in the HD transgenic model,34 a long latent period is necessary for inclusions to induce neuronal death. Neurons, as postmitotic cells, may be specifically affected because they survive long enough for the inclusions to have effect, whereas nonneural cells with nuclear inclusions turn over before the inclusions have pathological consequences. The significantly lower frequency of nuclear inclusion in nonneural tissues than in neurons may support this view. These differences in cell turnover rates could contribute to selective neuronal degeneration and neuronal loss.
Another interesting observation in this study is that the presence of nuclear inclusions is also selective among the various nonneural tissues, as it is in neural tissues. The inclusions are frequent in scrotal skin, dermal skin, and kidney; only occasionally seen in the testis and heart muscle; and not detected in spleen, liver, and muscle. The distribution of inclusions is not related to the expression level of mutant AR in these tissues.33 AR protein is highly expressed in the testis, skin, and muscle, whereas it is low in the kidney, spleen, and liver.33 A similar lack of correlation between the AR protein expression levels and pathological involvement is seen in the nervous system; neurons in Onuf's nuclei and Purkinje cells, for example, express a relatively large amount of AR protein,33 but these neurons are not affected in SBMA. The underlying mechanism that induces the selective formation of nuclear inclusions in neural as well as nonneural tissues remains undetermined; specific factors may be present only in the tissues with the nuclear inclusions, such as a protease that cleaves the N-terminal portion from the full-length AR protein, or specific proteins that interact with the mutant AR, as demonstrated in SCA123,26 and HD,21,22,24,25 may contribute to the cell type-specific formation of the nuclear inclusions. Alternatively, a degenerative process leading to apoptotic cell death with activation of a protease such as caspase 3 may be involved in the formation of nuclear inclusions as proposed in HD, DRPLA, MJD, and SBMA.41,42 Furthermore, the tissue-specific inclusion formation could be influenced by the different AR functional activity among the different tissues. The nonneural tissues we found to contain nuclear inclusions have relatively rapid cell turnover, with physiological cell degeneration and cell death.
In summary, cell type-specific nuclear inclusions are present in the nonneural as well as neural tissues in SBMA, but the high physiological rate of cell turnover may contribute to the absence of functional impairment with the formation of nuclear inclusions in the nonneural tissues.
| Footnotes |
|---|
This work was supported by grants from the Ministry of Health and Welfare of Japan, the Muscular Dystrophy Association, the National Institutes of Health, and the Kanae Foundation for Life and Medical Science, and by a Center of Excellence grant from the Ministry of Education, Science and Culture of Japan.
Accepted for publication June 25, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Adachi, M. Waza, K. Tokui, M. Katsuno, M. Minamiyama, F. Tanaka, M. Doyu, and G. Sobue CHIP Overexpression Reduces Mutant Androgen Receptor Protein and Ameliorates Phenotypes of the Spinal and Bulbar Muscular Atrophy Transgenic Mouse Model J. Neurosci., May 9, 2007; 27(19): 5115 - 5126. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Li, E. S. Chevalier-Larsen, D. E. Merry, and M. I. Diamond Soluble Androgen Receptor Oligomers Underlie Pathology in a Mouse Model of Spinobulbar Muscular Atrophy J. Biol. Chem., February 2, 2007; 282(5): 3157 - 3164. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Atsuta, H. Watanabe, M. Ito, H. Banno, K. Suzuki, M. Katsuno, F. Tanaka, A. Tamakoshi, and G. Sobue Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients Brain, June 1, 2006; 129(6): 1446 - 1455. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Adachi, M. Katsuno, M. Minamiyama, M. Waza, C. Sang, Y. Nakagomi, Y. Kobayashi, F. Tanaka, M. Doyu, A. Inukai, et al. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients Brain, March 1, 2005; 128(3): 659 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Everett and N. W. Wood Trinucleotide repeats and neurodegenerative disease Brain, November 1, 2004; 127(11): 2385 - 2405. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Minamiyama, M. Katsuno, H. Adachi, M. Waza, C. Sang, Y. Kobayashi, F. Tanaka, M. Doyu, A. Inukai, and G. Sobue Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy Hum. Mol. Genet., June 1, 2004; 13(11): 1183 - 1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Chevalier-Larsen, C. J. O'Brien, H. Wang, S. C. Jenkins, L. Holder, A. P. Lieberman, and D. E. Merry Castration Restores Function and Neurofilament Alterations of Aged Symptomatic Males in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy J. Neurosci., May 19, 2004; 24(20): 4778 - 4786. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hishikawa, J.-i. Niwa, M. Doyu, T. Ito, S. Ishigaki, Y. Hashizume, and G. Sobue Dorfin Localizes to the Ubiquitylated Inclusions in Parkinson's Disease, Dementia with Lewy Bodies, Multiple System Atrophy, and Amyotrophic Lateral Sclerosis Am. J. Pathol., August 1, 2003; 163(2): 609 - 619. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ishihara, N. Yamagishi, Y. Saito, H. Adachi, Y. Kobayashi, G. Sobue, K. Ohtsuka, and T. Hatayama Hsp105{alpha} Suppresses the Aggregation of Truncated Androgen Receptor with Expanded CAG Repeats and Cell Toxicity J. Biol. Chem., June 27, 2003; 278(27): 25143 - 25150. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Adachi, M. Katsuno, M. Minamiyama, C. Sang, G. Pagoulatos, C. Angelidis, M. Kusakabe, A. Yoshiki, Y. Kobayashi, M. Doyu, et al. Heat Shock Protein 70 Chaperone Overexpression Ameliorates Phenotypes of the Spinal and Bulbar Muscular Atrophy Transgenic Mouse Model by Reducing Nuclear-Localized Mutant Androgen Receptor Protein J. Neurosci., March 15, 2003; 23(6): 2203 - 2211. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Walcott and D. E. Merry Ligand Promotes Intranuclear Inclusions in a Novel Cell Model of Spinal and Bulbar Muscular Atrophy J. Biol. Chem., December 20, 2002; 277(52): 50855 - 50859. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. McManamny, H. S. Chy, D. I. Finkelstein, R. G. Craythorn, P. J. Crack, I. Kola, S. S. Cheema, M. K. Horne, N. G. Wreford, M. K. O'Bryan, et al. A mouse model of spinal and bulbar muscular atrophy Hum. Mol. Genet., September 1, 2002; 11(18): 2103 - 2111. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Caplen, J. P. Taylor, V. S. Statham, F. Tanaka, A. Fire, and R. A. Morgan Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference Hum. Mol. Genet., January 1, 2002; 11(2): 175 - 184. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sathasivam, B. Woodman, A. Mahal, F. Bertaux, E. E. Wanker, D. T. Shima, and G. P. Bates Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients Hum. Mol. Genet., October 1, 2001; 10(21): 2425 - 2435. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Adachi, A. Kume, M. Li, Y. Nakagomi, H. Niwa, J. Do, C. Sang, Y. Kobayashi, M. Doyu, and G. Sobue Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death Hum. Mol. Genet., May 1, 2001; 10(10): 1039 - 1048. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Abel, J. Walcott, J. Woods, J. Duda, and D. E. Merry Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice Hum. Mol. Genet., January 1, 2001; 10(2): 107 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. McCampbell, J. P. Taylor, A. A. Taye, J. Robitschek, M. Li, J. Walcott, D. Merry, Y. Chai, H. Paulson, G. Sobue, et al. CREB-binding protein sequestration by expanded polyglutamine Hum. Mol. Genet., September 1, 2000; 9(14): 2197 - 2202. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Becker, E. Martin, J. Schneikert, H. F. Krug, and A. C.B. Cato Cytoplasmic Localization and the Choice of Ligand Determine Aggregate Formation by Androgen Receptor with Amplified Polyglutamine Stretch J. Cell Biol., April 17, 2000; 149(2): 255 - 262. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Cummings and H. Y. Zoghbi Fourteen and counting: unraveling trinucleotide repeat diseases Hum. Mol. Genet., April 1, 2000; 9(6): 909 - 916. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kobayashi, A. Kume, M. Li, M. Doyu, M. Hata, K. Ohtsuka, and G. Sobue Chaperones Hsp70 and Hsp40 Suppress Aggregate Formation and Apoptosis in Cultured Neuronal Cells Expressing Truncated Androgen Receptor Protein with Expanded Polyglutamine Tract J. Biol. Chem., March 17, 2000; 275(12): 8772 - 8778. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Simeoni, M. A. Mancini, D. L. Stenoien, M. Marcelli, N. L. Weigel, M. Zanisi, L. Martini, and A. Poletti Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract Hum. Mol. Genet., January 1, 2000; 9(1): 133 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. Nazareth, D. L. Stenoien, W. E. Bingman III, A. J. James, C. Wu, Y. Zhang, D. P. Edwards, M. Mancini, M. Marcelli, D. J. Lamb, et al. A C619Y Mutation in the Human Androgen Receptor Causes Inactivation and Mislocalization of the Receptor with Concomitant Sequestration of SRC-1 (Steroid Receptor Coactivator 1) Mol. Endocrinol., December 1, 1999; 13(12): 2065 - 2075. [Abstract] [Full Text] |
||||
![]() |
M. D. Kaytor, L. A. Duvick, P. J. Skinner, M. D. Koob, L. P. W. Ranum, and H. T. Orr Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7 Hum. Mol. Genet., September 1, 1999; 8(9): 1657 - 1664. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, S.-H. Li, A. L. Cheng, L. Mangiarini, G. P. Bates, and X.-J. Li Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice Hum. Mol. Genet., July 1, 1999; 8(7): 1227 - 1236. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE |